68Ga-PSMA引导的骨活检用于转移性前列腺癌患者的分子诊断
这项前瞻性多中心全基因组测序试验纳入69例转移性前列腺癌患者,在骨活检前进行68Ga-PSMA PET/CT,评估68Ga-PSMA引导骨活检用于分子诊断的成功率。结果显示成功率为70%,68Ga-PSMA摄取阳性部位活检肿瘤阳性率70%,且68Ga-PSMA摄取(SUVmax)和放射密度(平均Hounsfield单位)均为阳性活检的强预测因素,曲线下面积分别为0.84和0.70。作者认为68Ga-PSMA PET/CT可考虑用于临床实践和临床试验中骨活检的引导。
要点
- 68Ga-PSMA引导骨活检用于分子分析的成功率为70%。
- 68Ga-PSMA摄取阳性、不确定、阴性部位活检肿瘤阳性率分别为70%、64%、36%(P=0.0610)。
- 68Ga-PSMA摄取(SUVmax)和放射密度(平均Hounsfield单位)预测阳性活检的曲线下面积分别为0.84和0.70。
核心结论
- 在转移性前列腺癌患者中,68Ga-PSMA PET/CT提高了CT引导骨活检用于分子分析的成功率,从而在更多患者中识别出可操作的体细胞变异。
- 因此,作者认为68Ga-PSMA PET/CT可考虑用于临床实践和临床试验中骨活检的引导。
研究设计与样本
- 前瞻性多中心全基因组测序试验(NCT01855477)纳入69例转移性前列腺癌患者,骨活检前接受68Ga-PSMA PET/CT。
- 主要终点为68Ga-PSMA引导骨活检的成功率(肿瘤百分比≥30%)。
- 通过刚性体图像配准68Ga-PSMA PET/CT与介入CT,在活检部位量化68Ga-PSMA摄取,并识别可操作的体细胞变异。
主要发现
- 68Ga-PSMA引导活检用于分子分析的成功率为70%。
- 在68Ga-PSMA摄取阳性、不确定、阴性部位,活检肿瘤阳性(≥30%)率分别为70%、64%、36%(P=0.0610)。
- 肿瘤阳性活检中,68Ga-PSMA摄取显著更高(P=0.008),而放射密度显著更低(P=0.006)。
- 68Ga-PSMA摄取(SUVmax)和放射密度(平均Hounsfield单位)预测阳性活检的曲线下面积分别为0.84和0.70。
- 在已测序活检中,73%检测到可操作的体细胞变异。
关键数值与推荐
- 活检成功定义为肿瘤百分比≥30%。
- 68Ga-PSMA摄取阳性、不确定、阴性部位活检肿瘤阳性率分别为70%、64%、36%(P=0.0610)。
- 68Ga-PSMA摄取(SUVmax)预测阳性活检的曲线下面积为0.84。
- 放射密度(平均Hounsfield单位)预测阳性活检的曲线下面积为0.70。
临床怎么用
- 作者认为,68Ga-PSMA PET/CT可考虑用于临床实践和临床试验中骨活检的引导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For individual treatment decisions in patients with metastatic prostate cancer (mPC), molecular diagnostics are increasingly used. Bone metastases are frequently the only source for obtaining metastatic tumor tissue. However, the success rate of CT-guided bone biopsies for molecular analyses in mPC patients is approximately only 40%. PET using 68Ga prostate-specific membrane antigen (68Ga-PSMA) is a promising tool to improve the harvest rate of bone biopsies for molecular analyses. The aim of this study was to determine the success rate of 68Ga-PSMA-guided bone biopsies for molecular diagnostics in mPC patients. Methods: Within a prospective multicenter whole-genome sequencing trial (NCT01855477), 69 mPC patients underwent 68Ga-PSMA PET/CT before bone biopsy. The primary endpoint was the success rate (tumor percentage ≥ 30%) of 68Ga-PSMA-guided bone biopsies. At biopsy sites, 68Ga-PSMA uptake was quantified using rigid-body image registration of 68Ga-PSMA PET/CT and interventional CT. Actionable somatic alterations were identified. Results: The success rate of 68Ga-PSMA-guided biopsies for molecular analyses was 70%. At biopsy sites categorized as positive, inconclusive, or negative for 68Ga-PSMA uptake, 70%, 64%, and 36% of biopsies were tumor-positive (≥30%), respectively (P = 0.0610). In tumor-positive biopsies, 68Ga-PSMA uptake was significantly higher (P = 0.008), whereas radiodensity was significantly lower (P = 0.006). With an area under the curve of 0.84 and 0.70, both 68Ga-PSMA uptake (SUVmax) and radiodensity (mean Hounsfield units) were strong predictors for a positive biopsy. Actionable somatic alterations were detected in 73% of the sequenced biopsies. Conclusion: In patients with mPC, 68Ga-PSMA PET/CT improves the success rate of CT-guided bone biopsies for molecular analyses, thereby identifying actionable somatic alterations in more patients. Therefore, 68Ga-PSMA PET/CT may be considered for guidance of bone biopsies in both clinical practice and clinical trials.
引用
- de Jong AC, Smits M, van Riet J, et al. 68Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. J Nucl Med. 2020. PMID: 32169916. doi:10.2967/jnumed.119.241109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。